CA3179630A1 - Formulations and methods for treating erectile dysfunction - Google Patents
Formulations and methods for treating erectile dysfunction Download PDFInfo
- Publication number
- CA3179630A1 CA3179630A1 CA3179630A CA3179630A CA3179630A1 CA 3179630 A1 CA3179630 A1 CA 3179630A1 CA 3179630 A CA3179630 A CA 3179630A CA 3179630 A CA3179630 A CA 3179630A CA 3179630 A1 CA3179630 A1 CA 3179630A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- vardenafil
- organic
- solubility
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029881P | 2020-05-26 | 2020-05-26 | |
| US63/029,881 | 2020-05-26 | ||
| PCT/US2021/034334 WO2021242913A1 (en) | 2020-05-26 | 2021-05-26 | Formulations and methods for treating erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179630A1 true CA3179630A1 (en) | 2021-12-02 |
Family
ID=78722740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179630A Pending CA3179630A1 (en) | 2020-05-26 | 2021-05-26 | Formulations and methods for treating erectile dysfunction |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240216383A1 (https=) |
| EP (1) | EP4157449A4 (https=) |
| JP (1) | JP2024521765A (https=) |
| KR (1) | KR20240013128A (https=) |
| CN (1) | CN116568289A (https=) |
| AU (1) | AU2021280285A1 (https=) |
| BR (1) | BR112022024098A2 (https=) |
| CA (1) | CA3179630A1 (https=) |
| IL (1) | IL298432A (https=) |
| WO (2) | WO2021242913A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL247528B1 (pl) * | 2023-04-08 | 2025-07-21 | Sativa Med Spolka Akcyjna | Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2391968A1 (en) * | 1999-11-18 | 2001-05-25 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| DE10118306A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| US20060051413A1 (en) * | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
| DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| US20060207596A1 (en) * | 2005-03-18 | 2006-09-21 | Fairfield Clinical Trials, Llc | Device and method for delivery of combination nasal medication |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| MX2010004265A (es) * | 2007-10-19 | 2010-07-28 | Innozen Inc | Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo. |
| GB2497933B (en) * | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| US20140271847A1 (en) * | 2013-03-13 | 2014-09-18 | SatisPharma, LLC | Formulations and methods for rapid penile erections |
| US20170014417A1 (en) * | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
| CN111655229A (zh) * | 2017-12-20 | 2020-09-11 | 卡里亚制药控股有限公司 | 包含伐地那非的薄膜制剂、其制备方法及其用途 |
| US11648197B2 (en) * | 2018-06-28 | 2023-05-16 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
-
2021
- 2021-05-26 IL IL298432A patent/IL298432A/en unknown
- 2021-05-26 AU AU2021280285A patent/AU2021280285A1/en active Pending
- 2021-05-26 BR BR112022024098A patent/BR112022024098A2/pt unknown
- 2021-05-26 WO PCT/US2021/034334 patent/WO2021242913A1/en not_active Ceased
- 2021-05-26 EP EP21811862.8A patent/EP4157449A4/en active Pending
- 2021-05-26 CA CA3179630A patent/CA3179630A1/en active Pending
- 2021-12-01 WO PCT/US2021/061488 patent/WO2022250731A1/en not_active Ceased
- 2021-12-01 US US17/999,826 patent/US20240216383A1/en active Pending
- 2021-12-01 KR KR1020237040722A patent/KR20240013128A/ko active Pending
- 2021-12-01 CN CN202180076999.6A patent/CN116568289A/zh active Pending
- 2021-12-01 JP JP2023572709A patent/JP2024521765A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021242913A1 (en) | 2021-12-02 |
| IL298432A (en) | 2023-01-01 |
| EP4157449A1 (en) | 2023-04-05 |
| BR112022024098A2 (pt) | 2023-02-07 |
| WO2022250731A1 (en) | 2022-12-01 |
| JP2024521765A (ja) | 2024-06-04 |
| US20240216383A1 (en) | 2024-07-04 |
| KR20240013128A (ko) | 2024-01-30 |
| CN116568289A (zh) | 2023-08-08 |
| AU2021280285A1 (en) | 2023-02-02 |
| EP4157449A4 (en) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12268686B2 (en) | Transmucosal methods for treating psychiatric and neurological conditions | |
| US12144808B2 (en) | Compositions and methods | |
| US8592406B2 (en) | Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant | |
| CN104173286B (zh) | 氮卓斯汀组合物和用途 | |
| CA3179630A1 (en) | Formulations and methods for treating erectile dysfunction | |
| CA2391968A1 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
| CN101534804B (zh) | 经鼻抗惊厥药物组合物 | |
| US12324811B2 (en) | Intranasal formulation | |
| Park et al. | Can currently available drugs for erectile dysfunction be re-formulated to achieve rapid effect? | |
| WO2024141623A1 (en) | Liquid pharmaceutical formulations of quinolines | |
| HK40098632A (zh) | 治疗勃起功能障碍的配方和方法 | |
| WO2026043819A1 (en) | Formulations and methods for convenient and rapid diuresis for the treatment of edema | |
| AU2019358394B2 (en) | Oromucosal solutions of Zolpidem or pharmaceutically acceptable salts thereof | |
| US20060193784A1 (en) | Scopolamine sublingual spray for the treatment of motion sickness | |
| WO2026062705A1 (en) | Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof | |
| WO2023108074A1 (en) | Novel salvinorin compositions | |
| JP2017523231A (ja) | 癌治療用アファチニブ医薬キット | |
| WO2022123433A1 (en) | Oral pharmaceutical compositions of remdesivir | |
| EA045748B1 (ru) | Раствор золпидема или его фармацевтически приемлемой соли для оромукозного введения для лечения бессонницы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250429 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250429 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250508 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250724 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250724 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20251223 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260304 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 |